Latest News

If you are wondering whether Hang Seng Bank's current share price offers good value or not, you are not alone. This article is written with that exact question in mind. The stock closed at HK$154.3, with returns of 0.5% over the last 30 days, 0.3% year to date and 74.5% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage around Hang Seng Bank has focused on its role as one of Hong Kong's major banking institutions...

In recent days, Chinese authorities reportedly moved to limit purchases of Nvidia’s H200 AI chips to special circumstances, while domestic AI developer Zhipu released a new model trained entirely on Huawei-made chips, reinforcing Beijing’s push for greater self-reliance in advanced semiconductors. This combination of tighter controls on foreign AI hardware and tangible progress in homegrown AI chip ecosystems has sharpened investor focus on how domestic foundries like Hua Hong Semiconductor...

Earlier this year, Bank of America raised its forecast for Hong Kong home prices for 2026 and 2027 and expressed a positive stance on Swire Properties, expecting a profit rebound supported by recovering residential and commercial real estate markets in key districts. A key nuance is Bank of America’s view that rising office rents in Central and Tsim Sha Tsui, contrasted with pressure in Kowloon and Hong Kong Island East, could create a two-speed rental landscape that matters for Swire...

In recent days, Centessa Pharmaceuticals reported new preclinical data showing its selective OX2R agonist reduced behavioral despair and improved wakefulness in animal models of major depressive disorder, while also outlining plans to broaden its orexin pipeline across neuropsychiatric conditions with high unmet need. Coupled with strong analyst support, leadership changes, and a planned US$250,000,000 public offering to fund late-stage trials, these developments highlight how Centessa is...

If you are wondering whether Robosense Technology’s recent share price reflects its real value, you are not alone. That is exactly what this article will help you unpack. The stock last closed at HK$39.86, with returns of 2.8% over 7 days, 10.4% over 30 days, 6.9% year to date and 35.6% over the last year. This performance has put the question of valuation firmly on the table. Recent coverage around Robosense Technology has focused on its position in the Hong Kong tech sector and investor...

Dream Industrial Real Estate Investment Trust (TSX:DIR.UN) is back in focus as its units respond to stronger industrial leasing demand and a more dovish interest rate outlook, which is reinforcing interest in its logistics focused portfolio. See our latest analysis for Dream Industrial Real Estate Investment Trust. At a unit price of CA$13.52, Dream Industrial REIT has seen its 30 day share price return of 7.22% build on a 90 day gain of 10.46%. Its 1 year total shareholder return of 22.73%...

With a price-to-earnings (or "P/E") ratio of 21.9x Wise plc ( LON:WISE ) may be sending bearish signals at the moment...

Recently, LexinFintech Holdings was featured in research on promising penny stocks, highlighting its strong financial health rating and position within China's consumer finance sector. An interesting angle from this coverage is that LexinFintech is being framed as a lower-priced entry point where fundamentals, rather than speculation, are the primary focus for investors. Against this backdrop of attention on LexinFintech’s financial strength, we’ll examine how this recognition may influence...

Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar Xeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock. See our latest analysis for Xeris Biopharma Holdings. The updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share...

Canaccord Genuity’s upgrade of Lovisa Holdings (ASX:LOV) to a more positive rating has put the fashion jewelry retailer back on investor watchlists, with the broker pointing to long term earnings potential as a key driver. See our latest analysis for Lovisa Holdings. The Canaccord call comes after a mixed stretch for investors, with a 6.4% 1 month share price return and a 5.3% 7 day share price return offset by an 18.5% 3 month share price decline, while the 5 year total shareholder return of...

In January 2026, Polestar Automotive Holding UK PLC reported fourth-quarter 2025 retail sales of 15,608 cars and full-year sales of 60,119, both higher than the prior year. This step-up in retail volumes suggests that Polestar is managing to increase customer deliveries even as competition in the global EV market intensifies. We will now examine how this acceleration in full-year retail sales intersects with concerns about cash burn, competition, and Polestar’s longer-term investment...

While CTS Eventim AG & Co. KGaA ( ETR:EVD ) might not have the largest market cap around , it saw significant share...

There wouldn't be many who think Reply S.p.A.'s ( BIT:REY ) price-to-earnings (or "P/E") ratio of 15.9x is worth a...

With a price-to-earnings (or "P/E") ratio of 13.7x Brembo N.V. ( BIT:BRE ) may be sending bullish signals at the...

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...

In December, Immunome, Inc. reported positive topline results from its Phase 3 RINGSIDE trial, showing Varegacestat improved progression-free survival versus placebo and plans to seek FDA approval in the second quarter of 2026. The data, including a marked reduction in the risk of death or disease progression and a high rate of tumor shrinkage, positions Varegacestat as a potentially important addition to Immunome’s oncology pipeline. Next, we’ll examine how Varegacestat’s strong Phase 3...

Recent comments from Constellation Software founder Mark Leonard, who said he wants his grandchildren to hold Lumine Group (TSXV:LMN) for life, have put fresh attention on the company and its telecom and media software focus. See our latest analysis for Lumine Group. Despite the renewed attention from Mark Leonard’s comments, Lumine Group’s share price has come under pressure, with a 30 day share price return of 10.27% and a 90 day share price return of 30.95%. However, the 1 year total...

Key Insights Given the large stake in the stock by institutions, Grupa Kety's stock price might be vulnerable to their...

Whilst it may not be a huge deal, we thought it was good to see that the SIG plc ( LON:SHI ) CEO & Director, Pim R...

Ignoring the stock price of a company, what are the underlying trends that tell us a business is past the growth phase...

We wouldn't blame Diploma PLC ( LON:DPLM ) shareholders if they were a little worried about the fact that Jonathan...

Key Insights HUTCHMED (China)'s significant retail investors ownership suggests that the key decisions are influenced...